ZytoVision

ZytoVision is a German molecular diagnostics company focused on in vitro diagnostic assays for pathology, especially cancer diagnostics based on in situ hybridization technologies. The company develops, manufactures, and sells fluorescence in situ hybridization and chromogenic in situ hybridization products, along with related reagents and workflow solutions for clinical laboratories. Its portfolio includes the ZytoLight, ZytoDot, ZytoFast, VisionArray, and ZytoMation product lines used to detect genetic aberrations, infectious agents, and other biomarkers in tissue and cytology samples. ZytoVision operates from Bremerhaven and is part of the broader ZYTOMICS group, which was assembled after ARCHIMED acquired the Zyto group in 2021. The business is commercial-stage rather than a therapeutic drug developer, serving pathology labs, hospitals, and diagnostic providers in precision oncology and related testing markets.